Work

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-8075

Authors: Amir Ali, Pallawi Torka, Yucai Wang, Tara Graff, Erin Mulvey, Yumeng Zhang, Monika Jun, Abualbishr Alshreef, Alex Mutebi, Anthony Wang, David Tybor, Lynn Huynh, Angela Lax, Tychell Branchcomb, Mei Sheng Duh, Javier Munoz, Muhamad Alhaj Moustafa, Nausheen Ahmed

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Weill Cornell Medicine, Moffitt Cancer Center, Genmab (United States), AbbVie (United States), Analysis Group (United States), Mayo Clinic in Florida, The University of Kansas Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417016680

Cites:

Cited by:

Related to: